GlassScriptPhysician profile
Benjamin Mastridge
NPI 1942421508
$7,863.28
in general payments reported to CMS, 2019-2025
20 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,363 · 2022: $1,457 · 2023: $1,442 · 2024: $1,659 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Education: $93.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.05 |
| Education | $93.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,506.21 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,119.89 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $799.98 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $796.11 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $723.97 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $674.05 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $573.58 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $397.18 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $364.43 | 2021-2025 | Hetlioz, Fanapt |
| Corium, LLC | $253.58 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $152.32 | 2025 | Cobenfy |
| Indivior INC. | $148.29 | 2021-2025 | Sublocade, Perseris |
| Almatica Pharma LLC | $112.89 | 2024-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $80.41 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $44.02 | 2022-2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34.97 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $28.90 | 2021 | |
| Lundbeck LLC | $21.85 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $15.45 | 2024 | |
| Bausch Health US, LLC | $15.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Mastridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.